High Levels of Pro B-Type Natriuretic Peptides Are Associated with Adverse Outcomes in COVID-19 Disease: A Single Center Experience


  •   Kashif Bin Naeem

  •   Najiba Abdulrazzaq


Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2, has caused widespread morbidity and mortality worldwide. Cardiac injury is reported to be common in hospitalized patients. We evaluated whether Pro B-type Natriuretic Peptide (proBNP) levels measured on admission in COVID-19 patients were associated with worse outcomes. A retrospective analysis of laboratory-confirmed COVID-19 patients who were admitted between February 2020 and July 2020 to Al Kuwait Hospital, Dubai, UAE. Patients were divided into two groups: normal proBNP (≤125 ng/L) and high proBNP (>125 ng/L) upon admission. Clinical characteristics and outcomes were compared between the two groups. A total of 389 patients were studied. Overall, mean age was 50.2 years (range 16-94 years), 77.3% were males, 35.7% diabetics, 35.2% hypertensives and 5.6% had history of cardiovascular disease. Compared to the group with normal proBNP; patients with high proBNP on admission were: older, more diabetics and hypertensives, with more history of cardiovascular disease; they presented with abnormal chest radiograph; and had lower lymphocytes, higher neutrophils, lower eGFR, higher D-dimers, higher CRP and higher procalcitonin on admission laboratory tests. These patients had more risk of developing critical illness during the hospitalization, undergoing mechanical ventilation and risk of death. Elevated pro B-type natriuretic peptide levels on admission in COVID-19 patients may predict subsequent risk of developing critical illness, undergoing mechanical ventilation, and significant high risk of death.

Keywords: COVID-19, pro B-type natriuretic peptide, outcomes


Zhu N, Zhang D, Wang W, eta l. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382:727-33.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb 15; 395(10223): 497-506.

Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia. JAMA. Published February 7, 2020. doi:10.1001/jama.2020.1585.

Zheng YY, Ma YT, Zhang JY, Xin X. COVID-19 and the cardiovascular system. Nat Rev Cardio 2020; 17:259-260.

de Bold AJ, Bornstein HB, Verses AT, Sonnenberg H. A rapid potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci. 1981 Jan 5;28(1):89–94.

Krishnaswami A. The role of B-type and other natriuretic peptides in health and disease. Perm J. 2008;12(4):32-43.

Donoghue M, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1–9.

Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona virus disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi. 2020;36:E005.

Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020.

Shi S, Qin M, Shen B, et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020.


Download data is not yet available.


How to Cite
Naeem, K. B., & Abdulrazzaq, N. (2020). High Levels of Pro B-Type Natriuretic Peptides Are Associated with Adverse Outcomes in COVID-19 Disease: A Single Center Experience. European Journal of Medical and Health Sciences, 2(5). https://doi.org/10.24018/ejmed.2020.2.5.480